FDA “Data Steward” Role Suggested By Industry In Lieu of Direct Release of NDA/BLAs
This article was originally published in RPM Report
FDA surprised a number of industry observers in June when the agency interpreted a call for “regulatory science” improvements from FDASIA to include release of NDA and BLA data. Instead of just objecting outright to the proposal, however, a number of biopharma groups have suggested other ways in which FDA can mine useful information from the dataset through collaborative relationships.
You may also be interested in...
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
Multiple simultaneous sponsors, foreshortened regulatory reviews, and a packet of unanswered post-approval efficacy issues make for what should be very competitive – and inherently comparative – post-market assessment period for the upcoming SARS-CoV-2 vaccines.
US FDA asks oncology drug sponsors for information on the impact of modifications to clinical trials during the pandemic – with close attention to remote monitoring and data collection.